Comments to Drs. Bahji, Vazquez, and Zarate

J Affect Disord. 2021 Mar 15;283:262-264. doi: 10.1016/j.jad.2021.01.046. Epub 2021 Jan 25.


In the absence of head-to-head studies directly comparing the efficacy of intranasal esketamine to that of intravenous ketamine, valid conclusions regarding comparative efficacy cannot be made based on the existing data from trials using markedly differing study designs and patient populations.

Keywords: Depression; Esketamine; Ketamine; Major depressive disorder.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antidepressive Agents / therapeutic use
  • Depression
  • Depressive Disorder, Major* / drug therapy
  • Depressive Disorder, Treatment-Resistant* / drug therapy
  • Humans
  • Ketamine* / therapeutic use


  • Antidepressive Agents
  • Esketamine
  • Ketamine